MedPath

A Multi-center Human Study to Evaluate the Efficacy and Safety of ®GI Flora in Subjects With Irritable Bowel Syndrome

Not Applicable
Conditions
Irritable Bowel Syndrome
Registration Number
NCT02419027
Lead Sponsor
Seoul National University Hospital
Brief Summary

A Multi-center, Randomized, Double-blinded, Placebo-controlled Human Study to Evaluate the Efficacy and Safety of probiotic mixture(®GI Flora) in Subjects with Irritable Bowel Syndrome.

Regimen: 6 probiotics mixture \>10\^9/D for 8 weeks

Primary variable: visual analogue scale(VAS) assessment for abdominal pain

Secondary variable:

1. change of VAS score for abdominal pain/discomfort after 4/8-week treatment

2. daily symptom score for bloating, defecation discomfort(strain/urgency/incomplete evacuation), flatulence , feces shape, frequency of bowel movements

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
116
Inclusion Criteria
  • Irritable bowel syndrome patients according to Rome III criteria
  • Recurrent abdominal pain or discomfort for at least 3 days per month in the last 3 months associated with at least 2 of the following characteristics: a) improvement with defecation; b) onset associated with a change in the frequency of stool; c) onset associated with a change in form (appearance) of stool.
Exclusion Criteria
  • Intolerable or hypersensitive to GI Flora.
  • Patients with active colon diverticulitis.
  • History of GI surgeries except hernia repair, appendectomy, primary closure due to perforation.
  • History of inflammatory bowel disease, malignancy requiring surgery or chemotherapy or radiation within 5 years.
  • Patient has any condition that, in the opinion of the Investigator, would compromise the well-being of the patient or the requirements of the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Visual Analogue Scale for abdominal pain8 weeks
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.